The numbers
The BA.3.2 variant of COVID-19, first identified in South Africa in November 2024, has quickly spread across the globe, detected in 29 U.S. states and Puerto Rico. As of March 12, 2026, BA.3.2 has been found in nasal swabs from six U.S. travelers, three airplane wastewater samples, 29 patients, and 260 wastewater samples, indicating a concerning level of transmission.
With approximately 70 to 75 mutations in its spike protein compared to the antigens used in current vaccines, BA.3.2 poses a significant challenge to existing immunization efforts. Laboratory studies suggest that this variant can efficiently evade antibodies, potentially reducing the effectiveness of vaccines against it. The prevalence of BA.3.2 detections among 5,238 sequences collected from December 1, 2025, to March 12, 2026, stands at 0.55%, highlighting its emerging presence in the viral landscape.
As of February 11, 2026, at least 23 countries have reported cases of BA.3.2, with its prevalence in some European nations reaching between 10% and 40%. This variant has also cocirculated with various JN.1 descendant lineages, complicating the public health response. Phylogenetic analyses have identified two sublineages of BA.3.2, designated BA.3.2.1 and BA.3.2.2, further diversifying the genetic landscape of SARS-CoV-2.
The public health impact of COVID-19 remains significant, with estimates suggesting 390,000 to 550,000 hospitalizations and 45,000 to 64,000 deaths during the 2024–2025 respiratory virus season. These figures underscore the ongoing threat posed by the virus, particularly as new variants like BA.3.2 emerge.
Wastewater surveillance has proven to be an effective early warning system for detecting BA.3.2, allowing health officials to monitor its spread more closely. Researchers emphasize that monitoring the spread of BA.3.2 provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.
Despite the alarming characteristics of BA.3.2, the first identification in the U.S. occurred on June 27, 2025, through the Traveler-Based Genomic Surveillance program. This highlights the importance of genomic surveillance in tracking the evolution of SARS-CoV-2 and understanding its implications for public health.
However, uncertainties remain regarding the impact of BA.3.2 on human health outcomes, and the extent of its geographic spread may be underestimated due to limited genomic detection capabilities in many countries. Continued genomic surveillance is needed to track SARS-CoV-2 evolution and determine its potential effect on public health. Details remain unconfirmed.
